TScan Therapeutics Files 8-K on Exit Activities
Ticker: TCRX · Form: 8-K · Filed: Nov 3, 2025 · CIK: 1783328
| Field | Detail |
|---|---|
| Company | Tscan Therapeutics, Inc. (TCRX) |
| Form Type | 8-K |
| Filed Date | Nov 3, 2025 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.0001, $2.3 million, $45.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, filing
TL;DR
TScan 8-K: Exit activities, Reg FD, and financials filed Nov 3, 2025.
AI Summary
TScan Therapeutics, Inc. filed an 8-K on November 3, 2025, reporting on cost associated with exit or disposal activities, Regulation FD disclosure, and other events. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located at 830 Winter Street, Waltham, Massachusetts.
Why It Matters
This 8-K filing indicates potential restructuring or divestiture activities within TScan Therapeutics, which could impact its future operations and strategic direction.
Risk Assessment
Risk Level: medium — Filings related to exit or disposal activities can signal significant business changes or financial distress, warranting closer investor scrutiny.
Key Players & Entities
- TScan Therapeutics, Inc. (company) — Registrant
- November 3, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 830 Winter Street, Waltham, Massachusetts 02451 (address) — Principal executive offices
- 001-40603 (company_id) — Commission File Number
- 82-5282075 (ein) — I.R.S. Employer Identification No.
FAQ
What specific 'Cost Associated with Exit or Disposal Activities' are detailed in this 8-K filing?
The filing mentions 'Cost Associated with Exit or Disposal Activities' as an item of disclosure but does not provide specific dollar amounts or details within the provided text.
What is the nature of the 'Other Events' reported by TScan Therapeutics?
The provided text for the 8-K filing lists 'Other Events' as a category of disclosure but does not specify what those events are.
When was TScan Therapeutics incorporated and in which state?
TScan Therapeutics, Inc. was incorporated in Delaware.
What is the primary business address for TScan Therapeutics?
The primary business address for TScan Therapeutics is 830 Winter Street, Waltham, Massachusetts 02451.
What is the Commission File Number for TScan Therapeutics?
The Commission File Number for TScan Therapeutics is 001-40603.
Filing Stats: 1,856 words · 7 min read · ~6 pages · Grade level 12.7 · Accepted 2025-11-03 06:35:34
Key Financial Figures
- $0.0001 — which registered Voting Common Stock, $0.0001 par value per share TCRX The Nasdaq
- $2.3 million — one-time charge of up to approximately $2.3 million during the three months ended December
- $45.0 million — ected to produce annual cost savings of $45.0 million in 2026 and 2027, and will impact appro
Filing Documents
- d873161d8k.htm (8-K) — 46KB
- d873161dex991.htm (EX-99.1) — 32KB
- d873161dex992.htm (EX-99.2) — 8KB
- g873161ex99_2s1g1.jpg (GRAPHIC) — 40KB
- g873161ex99_2s2g1.jpg (GRAPHIC) — 213KB
- g873161ex99_2s3g1.jpg (GRAPHIC) — 101KB
- g873161ex99_2s4g1.jpg (GRAPHIC) — 40KB
- g873161g1103044300776.jpg (GRAPHIC) — 4KB
- 0001193125-25-261612.txt ( ) — 766KB
- tcrx-20251103.xsd (EX-101.SCH) — 3KB
- tcrx-20251103_lab.xml (EX-101.LAB) — 18KB
- tcrx-20251103_pre.xml (EX-101.PRE) — 11KB
- d873161d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements that are based on the Company's beliefs and assumptions and on information currently available to the Company on the date of this Current Report. These forward-looking statements involve substantial risks and uncertainties. Any statements in this Current Report on Form 8-K other than statements of historical fact, including statements about the Company's future expectations, plans and prospects, constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, express or implied statements regarding expectations, hopes, beliefs, intentions or strategies of the Company regarding its strategic realignment, the workforce reduction, the costs associated therewith, and the benefits thereof, and anticipated cash runway, among others. In addition, any statements about the Company's strategy, operations and future expectations and plans and prospects for the Company, and any other statements containing the words "anticipate," "believe," "estimate," "expect," "intend", "goal," "may", "might," "plan," "predict," "project," "seek," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company's financial and operating results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements, including the factors discussed in the "Risk Factors" section contained in the quarterly and annual reports that the Company files with the Securities and Exchange Commission. Any forward-looking statements represent the Company's views only as of the date of this Current Report on Form 8-K. The Company anticipates that subsequent events and developments may cause its views
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by TScan Therapeutics, Inc., dated November 3, 2025 99.2 Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TScan Therapeutics, Inc. Date: November 3, 2025 By: /s/ Gavin MacBeath Gavin MacBeath Chief Executive Officer